🔴 IBRX is trading 5.6% down today as profit-taking continues after FDA-driven rally

IBRX is trading 5.6% down today at $7.31 as investors continue to lock in gains following a significant rally triggered by the FDA's sBLA acceptance for ANKTIVA plus BCG.

• The decline follows a 3.9% drop on May 21, signaling ongoing repositioning and profit-taking after the recent biotech surge.
• Today's move appears to be stock-specific rather than macro-driven, as major U.S. indices are trading modestly higher while traders rotate out of the name.